Aurobindo Pharma Q2 PAT may dip 28.3% YoY to Rs. 560 cr: HDFC Securities

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Aurobindo Pharma to report net profit at Rs. 560 crore down 28.3% year-on-year (up 9.8% quarter-on-quarter).

Net Sales are expected to decrease by 3.9 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 4,260 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 19.3 percent Y-o-Y (up 15.8 percent Q-o-Q) to Rs. 900 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More